AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging ...

A collaborative study led by Prof. Liu Guanghui from the Institute of Zoology of the Chinese Academy of Sciences and Dr. Wang ...

There was a dose-dependent, transient increase in serum ALT concentrations using the lentiviral vector not encoding accessory proteins (Fig. 3). In addition, the 8–10×10 8 TU dose of vector was ...

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...

A recent study on T cell gene therapy trials shows that while secondary malignancies occur in a small percentage of patients, ...

A collaborative study led by Prof. LIU Guanghui from the Institute of Zoology of the Chinese Academy of Sciences and Dr. WANG Si from Xuanwu Hospital ...

Oxford Biomedica plc (OTCMKTS:OXBDF – Get Free Report) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 78,300 shares, an increase of 131.0% ...

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the ...